Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2005

View Archived Issues

OX-22 completes efficacy study for insomnia

Mylan and King call off merger

Archimedes Pharma extends nasal drug delivery collaboration with Ionix

FDA extends PDUFA action date for nebivolol NDA

Orphan drug designation for Bronchitol in bronchiectasis

Sosei seeks Japanese approval for SOT-375

Intarcia begins phase III study for advanced breast cancer

MEM-3454 studied in phase I trial

BCY LifeSciences and Align sign agreement for DCF-987

Positive phase I findings for CYT006-AngQb for hypertension

Cytos Biotechnology reports 2004 achievements

Seikagaku completes phase I/II trial of SI-6603 for lumbar disc herniation

Recombinant human growth hormone studied in HIV+ patients with lipodystrophy

Tasmar receives European approval

Approvable letter for Glumetza

Second mutation in EGFR kinase domain confers resistance to gefitinib or erlotinib

Evidence supports the use of nicotine replacement therapies in heavy smokers

Allopurinol shows promise as add-on therapy for refractory schizophrenia

Chondroitinase shows promise in the management of spinal cord injuries

Prime-boost vaccine regimen active in infants of HIV-infected mothers

Extended treatment improves tacrolimus efficacy in myasthenia gravis

Modulators of amyloid beta levels claimed by Neurogenetics for Alzheimer's disease

Chemokine CCR5 receptor activators claimed by Ono

Eisai scientists disclose the neuroprotective activity of donepezil hydrochloride

Novel ALK-5 receptor inhibitors imparted by GSK

Bayer describes novel PDE9A inhibitors for Alzheimer's disease

AstraZeneca imparts the synthesis of three series of H+/K+-ATPase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...